Rapid communication Open Access
Like 0


To assess SARS-CoV-2 variants spread, we analysed 36,590 variant-specific reverse-transcription-PCR tests performed on samples from 12 April–7 May 2021 in France. In this period, contrarily to January–March 2021, variants of concern (VOC) β (B.1.351 lineage) and/or γ (P.1 lineage) had a significant transmission advantage over VOC α (B.1.1.7 lineage) in Île-de-France (15.8%; 95% confidence interval (CI): 15.5–16.2) and Hauts-de-France (17.3%; 95% CI: 15.9–18.7) regions. This is consistent with VOC β’s immune evasion abilities and high proportions of prior-SARS-CoV-2-infected persons in these regions.


Article metrics loading...

Loading full text...

Full text loading...



  1. World Health Organization (WHO). Tracking-SARS-CoV-2-variants. Geneva: WHO; 2021. [Accessed 1 Jun 2021]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
  2. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538):eabg3055.  https://doi.org/10.1126/science.abg3055  PMID: 33658326 
  3. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020;2020.12.21.20248640.
  4. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372(6544):815-21.  https://doi.org/10.1126/science.abh2644  PMID: 33853970 
  5. GISAID. "Tracking of Variants". gisaid.org. GISAID. [Accessed 30 May 2021]. Available from: https://www.gisaid.org/hcov19-variants/
  6. SARS-CoV-2 variant with lineage B.1.351 clusters investigation team. Linked transmission chains of imported SARS-CoV-2 variant B.1.351 across mainland France, January 2021. Euro Surveill. 2021;26(13):2100333.
  7. Haim-Boukobza S, Roquebert B, Trombert-Paolantoni S, Lecorche E, Verdurme L, Foulongne V, et al. Detecting Rapid Spread of SARS-CoV-2 Variants, France, January 26-February 16, 2021. Emerg Infect Dis. 2021;27(5):1496-9.  https://doi.org/10.3201/eid2705.210397  PMID: 33769253 
  8. Gaymard A, Bosetti P, Feri A, Destras G, Enouf V, Andronico A, et al. Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021. Euro Surveill. 2021;26(9):2100133.  https://doi.org/10.2807/1560-7917.ES.2021.26.9.2100133  PMID: 33663644 
  9. European Centre for Disease Prevention and Control (ECDC). SARS-CoV-2 variants of concern as of 24 May 2021. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/en/covid-19/variants-concern
  10. R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2015. Version 4.0.5. Available from: http://www.R-project.org/
  11. Chevin LM. On measuring selection in experimental evolution. Biol Lett. 2011;7(2):210-3.  https://doi.org/10.1098/rsbl.2010.0580  PMID: 20810425 
  12. Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (COVID-19) infections. Int J Infect Dis. 2020;93:284-6.  https://doi.org/10.1016/j.ijid.2020.02.060  PMID: 32145466 
  13. Le Vu S, Jones G, Anna F, Rose T, Richard J-B, Bernard-Stoecklin S, et al. Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance. Nat Commun. 2021;12(1):3025.  https://doi.org/10.1038/s41467-021-23233-6  PMID: 34021152 
  14. Roquebert B, Haim-Boukobza S, Trombert-Paolantoni S, Lecorche E, Verdurme L, Foulongne V, et al. SARS-CoV-2 variants of concern are associated with lower RT-PCR amplification cycles between January and March 2021 in France. medRxiv. 2021;2021.03.19.21253971.
  15. Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184(9):2348-2361.e6.  https://doi.org/10.1016/j.cell.2021.02.037  PMID: 33730597 
  16. Li Q, Nie J, Wu J, Zhang L, Ding R, Wang H, et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021;184(9):2362-2371.e9.  https://doi.org/10.1016/j.cell.2021.02.042  PMID: 33735608 
  17. Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021;NEJMoa2105000. PMID:33882219
  18. Sofonea MT, Boennec C, Michalakis Y, Alizon S. Two waves and a high tide: the COVID-19 epidemic in France. Anaesth Crit Care Pain Med. 2021;40(3):100881.  https://doi.org/10.1016/j.accpm.2021.100881  PMID: 33962051 
  19. Paireau J, Mailles A, Eisenauher C, de Laval F, Delon F, Bosetti P, et al. Early chains of transmission of COVID-19 in France. MedRxiv. 2020;2020.11.17.20232264.

Data & Media loading...

Supplementary data

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error